The FDA recently approved Vosevi-a fixed-dose combination tablet containing FDA-approved sofosbuvir and velpatasvir, and a new drug, voxilaprevi-to treat adults with the hepatitis C virus who do not have cirrhosis (liver disease).
The FDA recently approved Vosevi—a fixed-dose combination tablet containing FDA-approved sofosbuvir and velpatasvir, and a new drug, voxilaprevi—to treat adults with the hepatitis C virus (HCV) who do not have cirrhosis (liver disease).
Vosevi will be the first approved treatment for patients who have been treated with the direct-acting antiviral drug sofosbuvir or any other treatment that targets the NS5A protein.
“Direct-acting antiviral drugs prevent the virus from multiplying and often cure HCV,” Edward Cox, MD, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. “Vosevi provides a treatment option for some patients who were not successfully treated with other HCV drugs in the past.”
The FDA approval includes the treatment of hepatitis C genotypes 1-6 that are genetically distinct versions of the virus. Approximately, 75% of Americans with HCV have genotype 1; 20% to 25% have genotypes 2 or 3; and the small number of remaining patients have genotypes 4, 5, or 6. By identifying the genotype, more specific treatment recommendations of Vosevi can be made.
Approximately 750 adults with the HCV participated in two Phase 3 clinical trials in order to test the safety and effectiveness of Vosevi. The first trial, over the course of 12 weeks, compared genotype 1 patients, who received a placebo and had previously received an unsuccessful NS5A inhibitor, with patients with genotype 2, 3, 4, 5 or 6 who all received Vosevi. The second trial included a comparison of Vosevi and the previously approved drugs sofosbuvir and velpatasvir in patients with genotypes 1, 2, or 3 who had an unsuccessful treatment with sofosbuvir.
The trial revealed 96% to 97% of patients who received Vosevi had no detection of the virus at 12 weeks following the treatment—demonstrating a potential cure.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More